Genezen, a gene therapy contract development and manufacturing organization (CDMO), has welcomed Dr. Pam Stetkiewicz and Stuart Auerbach to its Board of Directors.
 
These board appointments bolster Genezen’s strategic growth plan and come at a time of significant momentum for the organization.

About Dr. Pam Stetkiewicz

Stetkiewicz brings significant gene therapy drug development and CMC experience to Genezen’s Board through her current position as Chief Operating Officer at Arbor Biotechnologies, a next-generation gene editing company combining the promise of CRISPR with advanced computational AI-driven discovery, high throughput screening, and robust protein engineering approaches.
 
Stetkiewicz previously held senior roles at Flagship Pioneering, Editas Medicine, and Novartis and has a PhD in Immunology from Johns Hopkins University.

About Stuart Auerbach

Auerbach brings a proven track record over the course of three decades in partnering with founders and management teams to successfully scale companies. He has been a key member of the investment team and member of the board of directors of numerous contract development and manufacturing organizations in both the therapeutics and medical device sectors.
 
Auerbach is currently serving as a Senior Advisor at Ampersand Capital Partners, a leading healthcare private equity investor, where he was a General Partner for more than twenty years. He has a B.S. in Chemical Engineering from Columbia University and an MBA from Harvard Business School.
 
Steve Favaloro, Chairman and CEO, said, “I am thrilled to welcome Pam and Stuart to our board at an exciting time in Genezen’s development. They bring a wealth of manufacturing, drug development, and strategic insight to the board, and I am excited to partner with them to continue to build our organization.”